What we still don’t know about vaccines

Hello,

Welcome to Insider Healthcare. I’m Lydia Ramsey Pflanzer, and this week in healthcare news:

If you’re new to this newsletter, sign up here. Tips, comments? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let’s get to it…


First, I wanted to introduce you to the newest member of our healthcare team!

Mohana Ravindranath joined us this week to cover the changing world of digital health. Before Insider, she was most recently covering health tech for Politico. She’s based in Washington, D.C.

Stay tuned for her reporting in the coming weeks, and in the meantime you can follow her on Twitter @ravindranize or shoot her an email at mravindranath@insider.com.


covid vaccine
A medical assistant administers a COVID-19 vaccine dose to a woman at a clinic in Los Angeles on March 25, 2021.

Unanswered vaccine questions

Coronavirus cases have fallen across the US to their lowest point since March 2020. Vaccines have played a major role in getting us to that point.

But there’s still reason to be cautious that we’re not beyond seeing another surge later this year, Andrew Dunn and Hilary Brueck report.

There’s still a lot to learn about how long protection from these vaccines last, and how they’ll fare against emerging variants as the coronavirus continues to spread globally.

Find out more>>

3 lingering questions about COVID-19 vaccines will shape the pandemic’s trajectory into 2022 and beyond


Ginkgo Bioworks
A biological engineer aliquots cells, separating out some of the material, at Ginkgo Bioworks.

Living up to the valuation

It seems like every week, there’s another healthcare company going public via SPAC.

This week, Allison DeAngelis took a closer look at the SPAC plans of synthetic biology company Ginkgo Bioworks.

The SPAC deal values the company at $15 billion.

But, Allison found, that valuation lies on some serious growth projections. And some experts are skeptical Ginkgo can live up to those projections.

Check it out>>

One giant question is swirling around Ginkgo’s record-setting SPAC deal: Can the hyped-up biotech live up to its $15 billion valuation?


DMT research at Imperial College London
DMT research at Imperial College London

The fight over the future of psychedelics

Patents are becoming a big issue in the field of psychedelic medicine, Yeji Jesse Lee reports.

Longtime activists are concerned the patents of companies developing psychedelic medications for potential approval could get in the way of access to those treatments.

Here’s what’s at stake>>

Experts share how a brewing fight could shape the future of the $100 billion psychedelics industry


More stories we have on our radar:


Don’t forget – we’re looking for nominees for our annual 30 under 40 list!

Know someone doing incredible work transforming the healthcare industry? Submit their name here.

Nominations are due by June 30.


– Lydia

Read the original article on Business Insider